

IN THE GENERAL DIVISION OF THE HIGH COURT
OF THE REPUBLIC OF SINGAPORE

Case No.: HC/OA /2026

In the matter of Section 210 of the Companies Act
1967

And

In the matter of Wave Life Sciences Ltd.

WAVE LIFE SCIENCES LTD.

(Singapore UEN No.: 201218209G)

...Applicant

REQUEST FOR URGENT HEARING BEFORE JUDGE

Case Number and Case Name	HC/OA /2026 In the matter of Wave Life Sciences Ltd.
Sub-Case Number(s) (if applicable)	N.A.
Name(s) of Applicant(s)	Wave Life Sciences Ltd. (Singapore UEN No. 201218209G)
Details of Applicant(s)	-
Counsel for Applicant(s) (if represented)	Daryl Xu Allen & Gledhill LLP
Contact Number(s) of Counsel for Applicant(s)	+65 9386 3478

<i>(if represented)</i> or of Applicant(s) <i>(if unrepresented)</i>	
Name(s) of Respondent(s)	N.A.
Counsel for Respondent(s) <i>(if represented)</i>	N.A.
Contact Number(s) of Counsel for Respondent(s) <i>(if represented)</i> or of Respondent(s) <i>(if unrepresented)</i>	N.A.
Summary of relief sought	Order for leave to be granted to the Applicant to convene a meeting of the holders of issued and paid-up ordinary shares in the capital of the Applicant (“ Shareholders ”) for the purposes of considering, and if thought fit, approving (with or without modification) a scheme of arrangement proposed to be made pursuant to Section 210 of the Companies Act 1967 (“ Companies Act ”) between (a) the Applicant, (b) the Shareholders, and (c) Wave Life Sciences, Inc, a Delaware corporation, in the manner set out in Schedule A to the Originating Application (Without Notice) (the “ Scheme ”).
Proposed hearing dates for the application(s)	A date in the week beginning 27 April 2026.

Estimated duration of the hearing	0.5 hours.
<p>Summary of relevant facts: (<i>Maximum 500 words</i>)</p> <ol style="list-style-type: none"> <li data-bbox="225 450 1370 551">1. The Applicant (the “Company”) is a Singapore-incorporated company that is listed on the Nasdaq Global Market (“Nasdaq”). <li data-bbox="225 600 1370 701">2. Wave Life Sciences, Inc (“Wave-Delaware”) is a corporation incorporated in Delaware, formed for the purposes of the Scheme. <li data-bbox="225 750 1370 851">3. The present application concerns a proposed redomiciliation of the Company from Singapore to Delaware (the “Redomiciliation”) by way of the Scheme. <li data-bbox="225 900 1370 1471">4. The Company intends to effect the Redomiciliation by way of the Scheme, under which all the issued and paid-up ordinary shares in the capital of the Company (the “Wave-Singapore Shares”) held by the Shareholders will be transferred to Wave-Delaware, and in consideration for the same, the Shareholders will receive one fully paid share of common stock of Wave-Delaware (“Wave-Delaware Common Stock”) for each Wave-Singapore Share transferred. Upon the Scheme taking effect, the shares of Wave-Delaware Common Stock will be listed on Nasdaq in place of the Wave-Singapore Shares, thereby completing the Redomiciliation. <li data-bbox="225 1520 1370 1890">5. Under Section 210(1) of the Companies Act, the Company requires leave of the Court to convene a meeting (the “Special Meeting”) of the Shareholders for the purposes of considering and if thought fit approving the Scheme. At the Special Meeting, the Scheme must be approved by three-fourths in value and a majority in number of the Shareholders (see Section 210(3AB)(a) and (b) of the Companies Act). If approved by the requisite majorities of Shareholders at the 	

Special Meeting, the Company will need to seek the Court's approval of the Scheme (see Section 210(3AB)(c) of the Companies Act).

6. The present application is the Company's application for leave to convene the Special Meeting. The Company seeks leave to convene the meeting in the manner set out in Schedule A to the Originating Application (Without Notice).

Reason(s) for urgency: (*Maximum 300 words*)

1. The proposed Redomiciliation is a price-sensitive transaction and may have a significant impact on the price of the Company's listed Wave-Singapore Shares.
2. The Company has filed a draft Proxy Statement for the Scheme with the United States Securities and Exchange Commission on 15 April 2026 as a publicly accessible document. The intention to undertake the Redomiciliation has also been publicly announced by the Company by way of a press release on 15 April 2026, which indicates that the target date for the Scheme to take effect is in mid-2026. Hence, there are public expectations as to the projected transaction timeline and dates. Accordingly, a prolonged / delayed timeline for progressing the Scheme will cause uncertainty amongst the investing public, and which will not be in the interests of the Shareholders.
3. The Company therefore respectfully seeks an early hearing date for its application, to facilitate the transaction occurring in line with the projected timelines and dates, so as to reasonably meet public expectations.
4. The Company is targeting to hold the Special Meeting on or around 9 June 2026. Under U.S. securities laws, the Proxy Statement (containing the Notice of Special Meeting) will need to be despatched at least 20 business days prior to the date of the meeting, and the finalised Proxy Statement is currently targeted to be despatched on or around 6 May 2026. Taking into account the lead time required

for finalisation of the Proxy Statement and printing of the document and proxy forms / notifications, the Applicant is seeking to obtain the leave of the Court by no later than the week commencing 27 April 2026.

5. The Company therefore humbly seeks the Court's indulgence in fixing an early hearing of the application on a date in the week beginning 27 April 2026.

Have all requisite Court papers been filed and are they in order?	Yes.
Is this an application without notice?	Yes.
Does paragraph 71 of the Supreme Court Practice Directions 2021 on applications without notice for injunctions apply?	No.
Has/Have the Applicant(s) notified the Respondent(s) of the attendance before the Duty Registrar?	N.A.
Has there been any previous request for an urgent hearing of the application(s)?	No.
Skeletal Submissions* (please select the applicable option):	
<input checked="" type="checkbox"/> I confirm that the skeletal submissions have been filed together with this Form.	

- The skeletal submissions could not be filed together with this Form, but will be filed as soon as possible and, in any event, no later than the next working day after the attendance before the Duty Registrar, unless the Court directs otherwise.
- Due to the extreme urgency, the skeletal submissions cannot be filed or provided in hard copy by the time of the hearing before the Judge, and I intend to seek a dispensation of this requirement at the hearing before the Judge.

Signature of Counsel for Applicant or of Applicant:



Name: Allen & Gledhill LLP

Date: 16 April 2026